Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALPINE IMMUNE SCIENCES, INC.NVLS · Entity 90802 | Exec Vice President and CMO | January 03, 2017 | January 05, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALPINE IMMUNE SCIENCES, INC.
Report date January 03, 2017 · Filed January 05, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,368 |
Ending reported balance
After 2017-01-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-01-03 · Exercise / conversion · Acquired 18,055 · Balance 18,055 F1: Represents shares issued on settlement of restricted stock units ("RSUs") granted to the reporting person upon vesting of such RSU's. Row 2 · 2017-01-04 · Sale · Disposed 6,687 · Balance 11,368 F2: Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person to cover tax obligations in connection with the vesting of RSUs. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.27 to $2.34, inclusive. The reporting person undertakes to provide Nivalis Therapeutics, Inc., any security holder of Nivalis Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 162,501 |
Reported balance
After 2017-01-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-01-03 · Exercise / conversion · Disposed 18,056 · Balance 162,501 F4: Represent fully vested RSUs. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal quarterly installments on the first day of each calendar quarter commencing July 1, 2016. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares issued on settlement of restricted stock units ("RSUs") granted to the reporting person upon vesting of such RSU's.
F2: Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person to cover tax obligations in connection with the vesting of RSUs.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.27 to $2.34, inclusive. The reporting person undertakes to provide Nivalis Therapeutics, Inc., any security holder of Nivalis Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.
F4: Represent fully vested RSUs. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal quarterly installments on the first day of each calendar quarter commencing July 1, 2016.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Mineralys Therapeutics, Inc.
Report date August 10, 2026 · Filed August 12, 2026
Section 16 reporting ended · disclosed 2026-08-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 51,384 |
Ending reported balance
After 2026-08-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-10 · Exercise / conversion · Acquired 2,170 · Balance 53,554 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Row 2 · 2026-08-10 · Sale · Disposed 2,170 · Balance 51,384 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2033-02-09 | Direct | 13,024 |
Reported balance
After 2026-08-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-10 · Exercise / conversion · Disposed 2,170 · Balance 13,024 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F2: The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.
F2: The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2024 Filed May 15, 2024 20:43 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 6,348 | $1.08 | $6,855.84 |
DisclosureSEC source: 0001628280-24-023621 · wk-form4_1715805784.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2024 Filed May 15, 2024 20:43 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 5,018 | $0.54 | $2,709.72 |
DisclosureSEC source: 0001628280-24-023621 · wk-form4_1715805784.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,015 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2024 Filed May 10, 2024 20:17 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 100 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001628280-24-022631 · wk-form4_1715372242.xml · derivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 203,054 Underlying: Common Stock · 100 shares Expires 2031-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2023. F3 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| May 09, 2024 Filed May 10, 2024 20:17 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 100 | $15.00 | $1,500.00 |
DisclosureSEC source: 0001628280-24-022631 · wk-form4_1715372242.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,997 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2023. Read SEC document |
| May 09, 2024 Filed May 10, 2024 20:17 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 100 | $1.08 | $108.00 |
DisclosureSEC source: 0001628280-24-022631 · wk-form4_1715372242.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2023. Read SEC document |
| April 12, 2024 Filed Apr 15, 2024 20:24 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 6,349 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001933414-24-000013 · wk-form4_1713212679.xml · derivative · entry 4 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,154 Underlying: Common Stock · 6,349 shares Expires 2031-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023. F4 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| April 12, 2024 Filed Apr 15, 2024 20:24 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 6,349 | $1.08 | $6,856.92 |
DisclosureSEC source: 0001933414-24-000013 · wk-form4_1713212679.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 11, 2024 Filed Apr 15, 2024 20:24 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 5,017 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001933414-24-000013 · wk-form4_1713212679.xml · derivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,156 Underlying: Common Stock · 5,017 shares Expires 2031-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023. F2 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| April 11, 2024 Filed Apr 15, 2024 20:24 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 5,017 | $0.54 | $2,709.18 |
DisclosureSEC source: 0001933414-24-000013 · wk-form4_1713212679.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 21:35 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 6,348 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001628280-24-011003 · wk-form4_1710365726.xml · derivative · entry 4 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,503 Underlying: Common Stock · 6,348 shares Expires 2031-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023. F4 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 21:35 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 6,348 | $1.08 | $6,855.84 |
DisclosureSEC source: 0001628280-24-011003 · wk-form4_1710365726.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 21:35 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 5,017 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001628280-24-011003 · wk-form4_1710365726.xml · derivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,173 Underlying: Common Stock · 5,017 shares Expires 2031-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023. F2 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 21:35 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 5,017 | $0.54 | $2,709.18 |
DisclosureSEC source: 0001628280-24-011003 · wk-form4_1710365726.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,283 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 21:26 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantStock Option · Derivative | 200,000 | $0.00 Strike: $14.25 | $0.00 |
DisclosureSEC source: 0001628280-24-005066 · wk-form4_1708032387.xml · derivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-02-13 F1 · derivative.exercise_date: The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter. Read SEC document |
| February 12, 2024 Filed Feb 13, 2024 21:08 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 6,349 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001933414-24-000007 · wk-form4_1707858518.xml · derivative · entry 4 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,851 Underlying: Common Stock · 6,349 shares Expires 2031-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023. F4 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| February 12, 2024 Filed Feb 13, 2024 21:08 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 5,017 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001933414-24-000007 · wk-form4_1707858518.xml · derivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,190 Underlying: Common Stock · 5,017 shares Expires 2031-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023. F2 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| February 12, 2024 Filed Feb 13, 2024 21:08 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 6,349 | $1.08 | $6,856.92 |
DisclosureSEC source: 0001933414-24-000007 · wk-form4_1707858518.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,266 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2024 Filed Feb 13, 2024 21:08 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 5,017 | $0.54 | $2,709.18 |
DisclosureSEC source: 0001933414-24-000007 · wk-form4_1707858518.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 12, 2024 Filed Jan 12, 2024 21:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 6,348 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001933414-24-000003 · wk-form4_1705093286.xml · derivative · entry 4 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,200 Underlying: Common Stock · 6,348 shares Expires 2031-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023. F5 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 12, 2024 Filed Jan 12, 2024 21:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 6,348 | $1.08 | $6,855.84 |
DisclosureSEC source: 0001933414-24-000003 · wk-form4_1705093286.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 11, 2024 Filed Jan 12, 2024 21:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 5,017 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001933414-24-000003 · wk-form4_1705093286.xml · derivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,207 Underlying: Common Stock · 5,017 shares Expires 2031-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023. F3 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 11, 2024 Filed Jan 12, 2024 21:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 5,017 | $0.54 | $2,709.18 |
DisclosureSEC source: 0001933414-24-000003 · wk-form4_1705093286.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,552 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This balance includes 1,466 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported. Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 22:08 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 5,018 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001933414-23-000094 · wk-form4_1702418911.xml · derivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,224 Underlying: Common Stock · 5,018 shares Expires 2031-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023. F2 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 22:08 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 5,018 | $0.54 | $2,709.72 |
DisclosureSEC source: 0001933414-23-000094 · wk-form4_1702418911.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,069 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2023 Filed Nov 14, 2023 23:18 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 5,017 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001933414-23-000091 · wk-form4_1700003914.xml · derivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,242 Underlying: Common Stock · 5,017 shares Expires 2031-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023. F2 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| November 13, 2023 Filed Nov 14, 2023 23:18 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 5,017 | $0.54 | $2,709.18 |
DisclosureSEC source: 0001933414-23-000091 · wk-form4_1700003914.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,051 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2023 Filed Nov 7, 2023 22:15 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 10,034 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001933414-23-000088 · wk-form4_1699395330.xml · derivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,259 Underlying: Common Stock · 10,034 shares Expires 2031-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023. F2 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| November 03, 2023 Filed Nov 7, 2023 22:15 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 10,034 | $0.54 | $5,418.36 |
DisclosureSEC source: 0001933414-23-000088 · wk-form4_1699395330.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 23:11 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 76,182 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001933414-23-000062 · wf-form4_169179547763057.xml · derivative · entry 9 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,548 Underlying: Common Stock · 76,182 shares Expires 2031-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023. F6 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 23:11 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 80,909 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001933414-23-000062 · wf-form4_169179547763057.xml · derivative · entry 8 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,293 Underlying: Common Stock · 80,909 shares Expires 2031-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023. F4 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 23:11 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 76,182 | $12.81 | $975,891.42 |
DisclosureSEC source: 0001933414-23-000062 · wf-form4_169179547763057.xml · nonDerivative · entry 6 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: The price reported is the weighted-average sales price, sold in multiple transactions at prices ranging from $12.39 to $13.185, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 23:11 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 76,182 | $1.08 | $82,276.56 |
DisclosureSEC source: 0001933414-23-000062 · wf-form4_169179547763057.xml · nonDerivative · entry 5 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,182 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 23:11 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 80,909 | $12.81 | $1,036,444.29 |
DisclosureSEC source: 0001933414-23-000062 · wf-form4_169179547763057.xml · nonDerivative · entry 4 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: The price reported is the weighted-average sales price, sold in multiple transactions at prices ranging from $12.39 to $13.185, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 23:11 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 80,909 | $0.54 | $43,690.86 |
DisclosureSEC source: 0001933414-23-000062 · wf-form4_169179547763057.xml · nonDerivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2023 Filed Aug 11, 2023 23:11 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 74,625 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001933414-23-000062 · wf-form4_169179547763057.xml · derivative · entry 7 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,202 Underlying: Common Stock · 74,625 shares Expires 2031-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023. F4 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| August 10, 2023 Filed Aug 11, 2023 23:11 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 74,625 | $13.16 | $982,065.00 |
DisclosureSEC source: 0001933414-23-000062 · wf-form4_169179547763057.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported is the weighted-average sales price, sold in multiple transactions at prices ranging from $13.00 to $13.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| August 10, 2023 Filed Aug 11, 2023 23:11 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 74,625 | $0.54 | $40,297.50 |
DisclosureSEC source: 0001933414-23-000062 · wf-form4_169179547763057.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 22:48 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001933414-23-000022 · wf-form4_167943889214123.xml · derivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-03-17 F1 · derivative.exercise_date: The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter. Read SEC document |
| February 09, 2023 Filed Feb 14, 2023 02:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantStock Option · Derivative | 104,186 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001628280-23-003423 · wf-form4_167634004383047.xml · derivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,186 Underlying: Common Stock · 104,186 shares Expires 2033-02-09 F1 · derivative.exercise_date: The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter. Read SEC document |
| January 04, 2017 Filed Jan 5, 2017 16:00 UTC | ALPINE IMMUNE SCIENCES, INC. NVLS · Entity 90802 | SaleCommon Stock | 6,687 | $2.27 | $15,179.49 |
DisclosureSEC source: 0001104659-17-000803 · a4.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Exec Vice President and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,368 F2 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person to cover tax obligations in connection with the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.27 to $2.34, inclusive. The reporting person undertakes to provide Nivalis Therapeutics, Inc., any security holder of Nivalis Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 16:00 UTC | ALPINE IMMUNE SCIENCES, INC. NVLS · Entity 90802 | Exercise / conversionRestricted Stock Units · Derivative | 18,056 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-000803 · a4.xml · derivative · entry 3 Rodman David Malcom · CIK 0001672659 · Exec Vice President and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,501 Underlying: Common Stock · 18,055 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Represent fully vested RSUs. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal quarterly installments on the first day of each calendar quarter commencing July 1, 2016. F4 · derivative.expiration_date: Represent fully vested RSUs. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal quarterly installments on the first day of each calendar quarter commencing July 1, 2016. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 16:00 UTC | ALPINE IMMUNE SCIENCES, INC. NVLS · Entity 90802 | Exercise / conversionCommon Stock | 18,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-000803 · a4.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Exec Vice President and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares issued on settlement of restricted stock units ("RSUs") granted to the reporting person upon vesting of such RSU's. Read SEC document |
| October 04, 2016 Filed Oct 5, 2016 20:16 UTC | ALPINE IMMUNE SCIENCES, INC. NVLS · Entity 90802 | SaleCommon Stock | 5,820 | $7.96 | $46,327.20 |
DisclosureSEC source: 0001104659-16-148903 · a4.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Exec Vice President and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,236 F2 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person to cover tax obligations in connection with the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.95 to $8.00, inclusive. The reporting person undertakes to provide Nivalis Therapeutics, Inc., any security holder of Nivalis Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 20:16 UTC | ALPINE IMMUNE SCIENCES, INC. NVLS · Entity 90802 | Exercise / conversionRestricted Stock Units · Derivative | 18,056 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-16-148903 · a4.xml · derivative · entry 3 Rodman David Malcom · CIK 0001672659 · Exec Vice President and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,556 Underlying: Common Stock · 18,056 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Represent fully vested RSUs. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal quarterly installments on the first day of each calendar quarter commencing July 1, 2016. F4 · derivative.expiration_date: Represent fully vested RSUs. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal quarterly installments on the first day of each calendar quarter commencing July 1, 2016. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 20:16 UTC | ALPINE IMMUNE SCIENCES, INC. NVLS · Entity 90802 | Exercise / conversionCommon Stock | 18,056 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-16-148903 · a4.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Exec Vice President and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares issued on settlement of restricted stock units ("RSUs") granted to the reporting person upon vesting of such RSU's. Read SEC document |
| September 12, 2016 Filed Sep 14, 2016 20:16 UTC | ALPINE IMMUNE SCIENCES, INC. NVLS · Entity 90802 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001104659-16-144636 · a4.xml · derivative · entry 1 Rodman David Malcom · CIK 0001672659 · Exec Vice President and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2026-09-12 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: The options vest and become exercisable over a four-year period, with 25% vesting on the first anniversary of the grant date (September 12, 2017) and 1/48th of the options vesting monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.